The second in a series of roundtables focused on clinical trial cost transparency

This policy is a commitment to publishing research protocols, registering clinical trials on appropriate registries, and subsequently publishing clinical trial data in open access formats, in line with the WHO’s joint statement on ...

Clinical trial cost transparency can inform evidence-based policy making and enable governments and treatment providers to regulate and negotiate prices more effectively.

Recommendations to member states to strengthen resolution on clinical trials at WHA75.

Affordable access to lifesaving vaccines not guaranteed as CEPI continues to avoid concrete commitments

Ahead of CEPI’s Board Meeting in Tokyo on 7–8 March 2019, MSF sent a letter to the organisation’s Board Members to express our concern and disappointment in CEPI’s revised Equitable Access Policy.

Our Lives on the Edge report looks at how pharmaceutical corporation practices keep crucial medical tools out of the hands of our teams. New and affordable drugs, vaccines and diagnostics are needed urgently. Find out why these life ...